Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis

被引:38
作者
McGarry, Meghan E. [1 ]
Gibb, Elizabeth R. [1 ]
Oates, Gabriela R. [2 ]
Schechter, Michael S. [3 ,4 ]
机构
[1] Univ Calif San Francisco, Dept Pediat, Div Pulm Med, San Francisco, CA 94110 USA
[2] Univ Alabama Birmingham, Dept Pediat, Div Pulm & Sleep Med, Birmingham, AL USA
[3] Virginia Commonwealth Univ, Dept Pediat, Div Pulm & Sleep Med, Richmond, VA USA
[4] Childrens Hosp Richmond VCU, Richmond, VA USA
关键词
Cystic fibrosis; CFTR modulators; Race; Ethnicity; CIGARETTE-SMOKE; TEZACAFTOR-IVACAFTOR; SOCIOECONOMIC-STATUS; DOUBLE-BLIND; HISPANIC PATIENTS; EPITHELIAL-CELLS; PHE508DEL CFTR; PARALLEL-GROUP; RISK-FACTORS; US FOOD;
D O I
10.1016/j.prrv.2021.12.001
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The advent of CFTR modulators, a genomic specific medication, revolutionized the treatment of CF for many patients. However, given that these therapeutics were only developed for specific CFTR mutations, not all people with CF have access to such disease-modifying drugs. Racial and ethnic minority groups are less likely to have CFTR mutations that are approved for CFTR modulators. This exclusion has the potential to widen existing health disparities.(c) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 114 条
[1]   Cystic fibrosis of the pancreas and its relation to celiac disease - A clinical and pathologic study [J].
Andersen, DH .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1938, 56 (02) :344-399
[2]  
[Anonymous], The Clinical and Functional TRanslation of CFTR (CFTR2) [Available from
[3]  
[Anonymous], 2019, NIH POLICY GUIDELINE
[4]  
[Anonymous], 2020, CYST FIBR FDN PAT RE
[5]   Tobacco smoke exposure limits the therapeutic benefit of tezacaf tor/ivacaf tor in pediatric patients with cystic fibrosis [J].
Baker, Elizabeth ;
Harris, William T. ;
Rowe, Steven M. ;
Rutland, Sarah B. ;
Oates, Gabriela R. .
JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (04) :612-617
[6]  
Balk E, 2018, MODULATOR TREATMENTS
[7]   Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study [J].
Barr, Helen L. ;
Britton, John ;
Smyth, Alan R. ;
Fogarty, Andrew W. .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
[8]   Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes [J].
Barry, Peter J. ;
Mall, Marcus A. ;
Alvarez, Antonio ;
Colombo, Carla ;
de Winter-de Groot, Karin M. ;
Fajac, Isabelle ;
McBennett, Kimberly A. ;
McKone, Edward F. ;
Ramsey, Bonnie W. ;
Sutharsan, Sivagurunathan ;
Taylor-Cousar, Jennifer L. ;
Tullis, Elizabeth ;
Ahluwalia, Neil ;
Jun, Lucy S. ;
Moskowitz, Samuel M. ;
Prieto-Centurion, Valentin ;
Tian, Simon ;
Waltz, David ;
Xuan, Fengjuan ;
Zhang, Yaohua ;
Rowe, Steven M. ;
Polineni, Deepika .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (09) :815-825
[9]   The future of cystic fibrosis care: a global perspective [J].
Bell, Scott C. ;
Mall, Marcus A. ;
Gutierrez, Hector ;
Macek, Milan ;
Madge, Susan ;
Davies, Jane C. ;
Burgel, Pierre-Regis ;
Tullis, Elizabeth ;
Castaos, Claudio ;
Castellani, Carlo ;
Byrnes, Catherine A. ;
Cathcart, Fiona ;
Chotirmall, Sanjay H. ;
Cosgriff, Rebecca ;
Eichler, Irmgard ;
Fajac, Isabelle ;
Goss, Christopher H. ;
Drevinek, Pavel ;
Farrell, Philip M. ;
Gravelle, Anna M. ;
Havermans, Trudy ;
Mayer-Hamblett, Nicole ;
Kashirskaya, Nataliya ;
Kerem, Eitan ;
Mathew, Joseph L. ;
McKone, Edward F. ;
Naehrlich, Lutz ;
Nasr, Samya Z. ;
Oates, Gabriela R. ;
O'Neill, Ciaran ;
Pypops, Ulrike ;
Raraigh, Karen S. ;
Rowe, Steven M. ;
Southern, Kevin W. ;
Sivam, Sheila ;
Stephenson, Anne L. ;
Zampoli, Marco ;
Ratjen, Felix .
LANCET RESPIRATORY MEDICINE, 2020, 8 (01) :65-124
[10]   Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation [J].
Berkers, Gitte ;
van der Meer, Renske ;
Heijerman, Harry ;
Beekman, Jeffrey M. ;
Boj, Sylvia F. ;
Vries, Robert G. J. ;
van Mourik, Peter ;
Doyle, Jamie R. ;
Audhya, Paul ;
Yuan, Zheng ;
Kinnman, Nils ;
van der Ent, C. Kors .
JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (05) :761-767